Skip to main content
Premium Trial:

Request an Annual Quote

454 Life Sciences Enters Research Collaboration with Broad Institute

This article has been updated from a previous version to reflect the research collaboration between the organizations.    

 

NEW YORK, Dec. 19 (GenomeWeb News) - 454 Life Sciences said today that it has entered into a research collaboration with the Broad Institute based on its Genome Sequencer 20 system.

 

According to 454, the Broad Institute will use the system to identify genomic mutations associated with various diseases such as cancer, diabetes, and heart disease.

 

"We hope this collaboration will lead not only to new insights into disease genomics, but also to the development of additional exciting applications for this promising technology," Chad Nusbaum, co-director of the Genome Sequencing and Analysis program at the Broad Institute, said in a statement.

 

Financial terms of the arrangement were not disclosed, but 454 said that the Broad Institute is the company's first customer for the commercially available version of the Genome Sequencer 20 system.

 

The company originally installed its system at the Broad in March.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.